Abstract: Methods or prevention or treatment of diseases or conditions caused by low plasma apoA-1 levels, the use of LRH1 activators in such methods and methods for identification of compounds useful in such treatment.

Abstract: Novel compounds of Formula (1) and esters, salts, and physiologically functional derivatives thereof are disclosed. Methods for preparing and using the compounds are also disclosed. Many of these compounds are selective activators of PPAR alpha. The compounds are particularly useful for treating obesity.

Abstract: Oxazole compounds having formula (I) wherein R.sup.1 and R.sup.3 are selected from the group consisting of hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkyl, phenyl or phenyl mono- or disubstituted with C.sub.1-6 alkyl, halogen, hydroxy, C.sub.1-6 alkoxy, aminosulfonyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkylsulfonylaminoC.sub.1-6 alkyl or carbamylC.sub.1-6 alkylaminosulfonyl; R.sup.2 is selected from hydrogen, C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxyC.sub.1-6 alkyl or (fluorinated C.sub.1-6 alkyl)oxyC.sub.1-6 alkyl; W is a C.sub.1-6 alkylene chain or nitrogen; m is independently the integer 0 or 1; X is CH or nitrogen, provided that when W is nitrogen then X is CH; q is independently an integer selected from the group consisting of 1, 2, 3 or 4; or a pharmaceutically acceptable acid-addition or base-addition salt thereof, pharmaceutical compositions containing them and their use in therapy.